Q3 2026 Charles River Laboratories International, Inc. Earnings Conference Call - CHARLES RIVER LABORATORIES INTERNATIONAL INC

Financial Performance:

• Third quarter revenue increased 4.7% year-over-year to a record high, with organic revenue growth of 4.7%, exceeding the prior outlook of 1-3%.
• Non-GAAP earnings per share (EPS) rose 27.2% YoY to $3.09, beating the prior guidance range due to top-line outperformance and a lower tax rate of 22.8%.
• Non-GAAP operating margin expanded 330 basis points YoY and 250 basis points sequentially to 23%, driven by operating leverage in DSA, lower non-human primate sourcing costs, and the full quarter impact of the CDMO divestiture in Manufacturing.
• DSA segment revenue grew 5.9% organically, with net bookings up 32% YoY to $652 million and a net book-to-bill ratio of 1.09x (averaging ~1.1x over the last four quarters).
• Manufacturing segment revenue rebounded with 7.4% organic growth, while Research Models & Services (RMS) declined 0.6% organically due to softer North American demand.
• Free cash flow totaled $207 million in Q3 (up $29 million YoY), with CapEx at $47 million.
• Net leverage improved to 2.3x at quarter-end due to lower debt levels and improved earnings.

Guidance and Future Outlook:

• Full-year 2026 organic revenue guidance raised by 100 basis points to >1.5% growth; reported revenue expected to decline 1.5%–2% due to divestitures.
• 2026 non-GAAP EPS guidance increased by $0.15 (midpoint) to the $11.35–$12.55 range, representing 10–12% YoY growth.
• 2027 outlook anticipates gradual growth improvement, targeting 5–7% organic revenue growth starting in 2028.
• 2027 is expected to see higher operating margin improvement than the long-term average due to full-year benefits from 2026 acquisitions/divestitures and $300M in "Create the Future" cost savings.
• Q4 2026 guidance embedded within full-year targets: DSA mid-single-digit growth, Manufacturing high-single-digit growth, and a modest RMS decline; operating margin expected to improve another ~150 bps.
• "Create the Future" transformation program targets $300 million in cumulative savings over four years, with meaningful margin impact expected in 2027.

Business Segments and Product Lines:

• DSA (Drug Safety Assessment): Driven by robust demand for non-human primate (NHP) studies and bioanalysis; margins improved 140 bps YoY to 26.8%.
• Manufacturing: Benefited from the CDMO divestiture and strong demand for endotoxin testing (EndoSafe) and biologics testing; margin expanded to 38.6%, approaching 40%.
• RMS (Research Models & Services): Growth constrained by North American academic/government headwinds but supported by double-digit growth in China and insourcing solutions.
• Product Launches: Implemented automated manufacturing suite for EndoSafe (14% capacity increase) and launched "Apollo Orchestrate" with Autolimus to digitize laboratory workflows.
• Innovation: Introduced a rapid cell banking program reducing biologics release timelines by 40%; advanced Virtual Control Groups (VCGs) to FDA-compliant status for an Ipsen study.
• Strategic Partnerships: Extended relationship with a top-10 biopharma client to serve as a primary strategic partner for safety assessment; FDA collaboration to validate preclinical screening tools for drug abuse potential.

Market and Competitive Landscape:

• Biopharmaceutical demand environment shows consistent momentum, with large biopharma clients reinvesting in R&D pipelines and biotech funding trailing 12 months near $100 billion.
• DSA pricing dynamics are shifting as the company begins modestly reducing discount levels, though pricing impact is not expected to reflect in revenue until H2 2027.
• Non-human primate supply remains a key differentiator; Charles River covers ~80% of its usage via owned farms, though supply in China is tight.
• AI is viewed as a long-term tailwind expected to increase the volume of programs entering IND-enabling and validation phases, though distinguishing AI-derived vs. legacy volumes is currently difficult.
• Competitive advantage identified in NHP supply chain control and preclinical bioanalysis capabilities.

Risks and Challenges:

• RMS segment faces continued headwinds from uncertainty in government funding and academic spending in North America.
• NHP supply chain constraints in China may affect pricing and availability, though the company maintains sufficient supply for its own needs.
• Pricing power in DSA has not yet materialized in top-line revenue due to the lag between proposal acceptance and study execution.
• Macroeconomic factors including inflation, interest rates, and oil prices are being monitored for potential disruptions to demand.
• Capital allocation discipline required to balance strategic acquisitions with debt repayment and cost-saving initiatives.

Management Commentary and Tone:

• Management expressed high confidence in the "Pathway to Purpose" strategy, citing progress in modernization, scientific leadership, and operational efficiency.
• Tone was optimistic regarding the accelerating revenue growth rate and margin expansion, describing the quarter as "solid" and results as exceeding prior outlook.
• Emphasis placed on simplifying the company, moving faster, and deepening client relationships through a customized, client-centric approach.
• CEO Birgit Gershick highlighted the company's positioning to capture share of R&D spend as demand trends improve.

Analyst Questions and Answers:

• Demand Drivers: Confirmed Q3 growth was volume-driven; pricing power improvements expected to materialize in H2 2027.
• AI Impact: AI-native biotechs tend to run more programs for validation purposes (increasing study volume), but no change in revenue per program; AI benefits will likely accelerate IND-enabling programs over the next 2 years.
• NHP Supply: 80% of NHP needs covered internally; China market supply is tight but currently non-material to revenue; pricing in China improved moderately.
• Therapeutic Areas: Strongest interest in complex biologics, mRNA, and ADCs; vaccine interest stable but not accelerating significantly.
• Capacity: Sufficient in vivo capacity exists for 2+ years; bioanalytical capacity is being expanded via five ongoing organic projects and potential M&A.
• Book-to-Bill: Q3 1.09x is considered a strong, clean number post-divestiture; backlog trends support long-term 5–7% DSA growth targets.
• Margin Mix: Lower SG&A and fringe costs in Q3 contributed to margin expansion, with further sequential improvements expected in Q4 due to NHP sourcing costs.

Other Key Points:

• The CDMO divestiture is now fully reflected in the financials, removing a previous headwind for the manufacturing segment and clarifying underlying margin trends.
• Tax rate outlook for 2026 is approximately 23%, lower than prior year due to favorable outcomes from global minimum tax provisions.
• "Create the Future" initiative includes over 500 ongoing modernization efforts aimed at driving efficiency and client connectivity.
• Virtual Control Groups (VCGs) are expected to provide revenue parity with traditional control groups while supporting ethical advancements in animal usage.
• Capital expenditure is expected to remain around $200 million for 2026, aligning with long-term targets of 5–6% of revenue.